Showing 4641-4650 of 10637 results for "".
Evaluating High- vs. Low-Dose Corticosteroids in Acute IPF Exacerbations
https://reachmd.com/programs/clinicians-roundtable/evaluating-high-vs-low-dose-corticosteroids-in-acute-ipf-exacerbations/35655/A recent study investigated whether pulse-dose corticosteroids offer a benefit over lower doses in managing acute exacerbations of idiopathic pulmonary fibrosis (IPF). Join Dr. Divya Shankar as she explains the real-world data, variability in prescribing patterns, and outcomes observed in differentTime to Recurrence and Early Risk Indicators in BRVO-Related Macular Edema
https://reachmd.com/programs/eye-on-ocular-health/time-to-recurrence-and-early-risk-indicators-in-brvo-related-macular-edema/54481/Modern Management of ROS1-Positive Non-Small Cell Lung Cancer
https://reachmd.com/programs/project-oncology/modern-management-of-ros1-positive-non-small-cell-lung-cancer/54574/Advances in Disease-Modifying and Curative Therapies for Sickle Cell Disease
https://reachmd.com/programs/project-oncology/advances-in-disease-modifying-and-curative-therapies-for-sickle-cell-disease/35928/Sickle cell disease management traditionally involves two primary treatment approaches: disease-modifying therapies and curative strategies. While disease-modifying therapies can help reduce complications associated with the disease, they do not correct or fix them, which is why curative strategiesConsequences of COVID-19: Addressing Infection-Associated Chronic Conditions
https://reachmd.com/programs/living-rheum/consequences-of-covid-19-addressing-infection-associated-chronic-conditions/32385/Patients experiencing post-acute infectious syndromes have been marginalized, but the advent of long COVID has highlighted their critical needs. Here’s what you should know.AEGEAN Trial: The Role of Perioperative Durvalumab in NSCLC
https://reachmd.com/programs/project-oncology/aegean-trial-the-role-of-perioperative-durvalumab-in-nsclc/16500/Explore the results of the AEGAN trial that focused on the use of neoadjuvant durvalumab in non-small cell lung cancer care.Beyond the Sum of Their Parts: Overcoming Disparities in Care
https://reachmd.com/programs/project-oncology/beyond-the-sum-of-their-parts-overcoming-disparities-in-care/13668/Find out more about the steps we can take to promote intersectionality and provide better patient care.Early Detection Shapes Outcomes in Post-Transplant Lung Cancer
https://reachmd.com/programs/project-oncology/early-detection-shapes-outcomes-in-post-transplant-lung-cancer/56342/Advancing Pediatric MS Care: Insights from AAN 2026
https://reachmd.com/programs/neurofrontiers/pediatric-ms-aan-2026/54250/At the 2026 American Academy of Neurology (AAN) Annual Meeting, experts are sharing the latest developments in pediatric multiple sclerosis (MS). Dr. Elizabeth Wilson is here to share insights on how new adult MS research, neuro-ophthalmology collaboration, and emerging clinical data are shaApplying CBT for Psychosis in Schizophrenia Care: Strategies for Expanding Access
https://reachmd.com/programs/neurofrontiers/applying-cbt-for-psychosis-in-schizophrenia-care-strategies-for-expanding-access/36647/Despite decades of evidence supporting cognitive behavioral therapy (CBT) for psychosis, most patients with schizophrenia in the U.S. never receive it due to systemic barriers like provider shortages and fragmented transitions after hospitalization. To address these gaps, Dr. David Kimhy joins Dr. C